CellCept mycophenolate mofetil: Completed Phase III enrollment

ASV completed enrollment of 77 patients in a double-blind, placebo-controlled, international Phase III trial. ASV has rights to develop CellCept for autoimmune indications from ROCZ, who markets CellC...